 |
|
|
| |
Pegylated Interferon-Lambda (PegIFN-λ) Shows Superior Viral Response With Improved Safety and Tolerability Versus PegIFN-α-2a in HCV Patients (G1/2/3/4): EMERGE Phase IIb Through Week 12
|
| |
| |
Reported by Jules Levin
46th EASL Congress, Berlin, Germany
March 30-April 3, 2011
S Zeuzem, S Arora, B Bacon, T Box, M Charlton, M Diago, D Dieterich, R Esteban Mur, G Everson, M Fallon, P Ferenci, R Flisiak, J George, R Ghalib, N Gitlin, A Gladysz, S Gordon, S Greenbloom, T Hassanein, I Jacobson, L Jeffers, K Kowdley, E Lawitz, S Lee, B Leggett, S Lueth, D Nelson, P Pockros, M Rodriguez-Torres, V Rustgi, L Serfaty, M Sherman, M Shiffman, R Sola, M Sulkowski, H Vargas, J Vierling, B Yoffe, L Ishak, D Fontana, D Xu, J Lester, T Gray, A Horga, J Hillson, E Ramos, JC Lopez-Talavera, A Muir, on behalf of the EMERGE Study Group
|
| |
|
|
|
|
|
